Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Transthyretin Amyloid Cardiomyopathy Gene Therapy Market: Nex-z Pivotal Outcomes Demand, LNP-Delivered CRISPR/Cas9 Editing Growth, and ATTRwt-CM Broad Patient Population Adoption to Drive Exceptional Market Expansion Through 2035

The global Transthyretin Amyloid Cardiomyopathy Gene Therapy Market is projected to expand at an exceptional CAGR of 34.0% through 2035, driven by sustained demand generated by the pivotal MAGNITUDE outcomes study evaluating nex-z, growing clinical validation of lipid nanoparticle-delivered CRISPR/Cas9 in-vivo gene editing, and continued focus on wild-type ATTR-CM as a large age-associated patient population alongside hereditary variant disease. Given data limitations in the underlying source figures for this specific sub-segment, this brief presents the CAGR-based growth outlook without specific market size figures. The market comprises nex-z (nexiguran ziclumeran) as the primary commercial and clinical benchmark, with its pivotal Phase 3 MAGNITUDE study evaluating a single 55-milligram infusion in approximately 1,200 adults with ATTR-CM.

The market’s exceptional 34.0% CAGR reflects the clinical translation of in-vivo CRISPR/Cas9 gene editing technology into a single-administration cardiovascular treatment approach, generating structured demand from specialized amyloidosis and heart failure treatment centers well above discretionary specialty pharmaceutical demand growth. Nex-z is designed to inactivate the TTR gene using an LNP-delivered CRISPR/Cas9 system, preventing hepatic production of TTR protein and thereby addressing both wild-type and hereditary variant forms of the disease through a single systemic infusion. Coverage extending across multiple ATTR types, delivery platforms, and cardiac disease severity classifications underscores the breadth of clinical infrastructure now supporting this category as its pivotal outcomes study progresses.

Executive Snapshot

How does nex-z pivotal outcomes demand drive the ATTR-CM gene therapy market?
Specialized amyloidosis and heart failure treatment centers continue to enroll patients across the pivotal MAGNITUDE Phase 3 study, which is evaluating a single 55-milligram infusion of nex-z in approximately 1,200 adults with ATTR-CM, establishing this trial as the central driver of near-term market development. As this pivotal program progresses toward completion, procurement associated with nex-z development is expected to remain the dominant category through the forecast period.

What role does LNP-delivered CRISPR/Cas9 editing growth play in market expansion?
Biopharmaceutical developers continue to rely on lipid nanoparticle-delivered CRISPR/Cas9 systems for systemic in-vivo TTR gene editing, consistent with nex-z’s design approach, sustaining structured demand from developers pursuing this delivery technology above AAV and other viral vector alternatives for hepatic gene inactivation.

How does ATTRwt-CM broad patient population adoption sustain market growth?
Treatment centers increasingly recognize wild-type ATTR-CM as a large age-associated patient population distinct from the genetically defined hereditary variant form, sustaining structured demand from developers pursuing this broader addressable market alongside mutation-specific hereditary ATTRv-CM treatment.

What is driving demand for gene editing in next-generation CRISPR-Cas3 approaches?
Developers pursuing CRISPR-Cas3-based TTR editing, which has recently demonstrated preclinical hepatic editing and TTR reduction, continue to advance this next-generation editing technology as a potential complement to established CRISPR-Cas9 approaches, generating incremental demand among clinical-stage biopharmaceutical developers pursuing differentiated editing platforms.

How does single-administration treatment demand sustain the market?
Treatment centers increasingly value the one-time treatment paradigm associated with in-vivo gene editing for TTR inactivation, sustaining structured demand from developers pursuing this differentiated treatment approach relative to chronic RNA-silencing or stabilizer therapy requiring ongoing administration.

Which ATTR-CM gene therapy market segments are growing fastest?
The fastest-growing segments include wild-type ATTR-CM applications, LNP-delivered systemic gene editing technology, next-generation CRISPR-Cas3 approaches, and Phase III pivotal-stage clinical development as the category approaches potential first approval.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Transthyretin Amyloid Cardiomyopathy Gene Therapy Market

  • Nex-z sustaining the leading share of clinical development activity within the category: As the primary clinical and commercial benchmark advancing through pivotal Phase 3 development, nex-z continues to anchor the substantial majority of current market activity.
  • CRISPR-Cas9 sustaining the dominant gene-editing technology across current clinical-stage programs: This editing platform continues to represent the leading approach relative to emerging CRISPR-Cas3 and other next-generation editing technologies.
  • Lipid nanoparticle delivery sustaining the dominant delivery platform for systemic in-vivo TTR editing: This delivery technology, central to nex-z’s design, continues to represent the leading approach relative to AAV and other viral vector alternatives.
  • Wild-type ATTR-CM sustaining a substantial and growing share of the addressable patient population: This large age-associated population continues to represent an important complement to genetically defined hereditary variant ATTR-CM.
  • Liver / hepatocyte targeting sustaining the primary molecular target across current gene-editing approaches: As the principal site of circulating TTR production, the liver continues to anchor current gene-editing therapeutic strategy.
  • Phase III pivotal-stage development sustaining the entirety of current market activity ahead of potential approval: The absence of a currently approved TTR-targeted gene-editing therapy continues to concentrate all market activity within late-stage clinical development.

Market Segmentation: Transthyretin Amyloid Cardiomyopathy Gene Therapy Market

By Product Type
  • Nex-z (nexiguran ziclumeran / NTLA-2001) – Intellia/Regeneron
  • Other
By Gene Therapy Modality
  • In-vivo gene editing
  • In-vivo gene silencing
  • Gene addition
  • Gene replacement
  • Gene modulation
  • RNA-mediated genetic modulation
  • Other genetic therapies
By Technology
  • CRISPR-Cas9
  • CRISPR-Cas3
  • CRISPR-Cas12
  • Base editing
  • Prime editing
  • Others
By Target
  • TTR gene
  • TTR coding region
  • TTR promoter/regulatory regions
  • Mutant TTR
  • Wild-type TTR
  • Mutant + wild-type TTR
  • Others
By Therapeutic Mechanism
  • Reduction of hepatic TTR synthesis
  • Reduction of circulating TTR
  • Prevention of new amyloid formation
  • Reduction of amyloid deposition
  • Potential mobilization/clearance of existing amyloid
  • Prevention of cardiomyocyte injury
  • Disease stabilization
  • Potential cardiac reverse remodeling
By Delivery Platform
  • Lipid nanoparticles (LNPs)
  • AAV
  • Others
By ATTR Type
  • Wild-type ATTR (ATTRwt-CM)
  • Hereditary/variant ATTR (ATTRv-CM)
  • Mixed / genotype-inclusive ATTR-CM
  • Mutation-specific ATTR-CM
By Disease Stage
  • Early-stage ATTR-CM
  • Mild cardiomyopathy
  • Moderate cardiomyopathy
  • Advanced cardiomyopathy
  • End-stage heart failure
By Target Organ
  • Liver / hepatocytes
  • Heart / myocardium
  • Cardiomyocytes
  • Vascular tissue
  • Peripheral tissues
  • Multi-organ targeting
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By End User
  • Specialized Amyloidosis Centers
  • Cardiology Hospitals
  • Heart-Failure Centers
  • Academic Medical Centers
  • Specialty Hospitals
  • Gene Therapy Centers
  • Cardiomyopathy Clinics
  • Neurology/Amyloidosis Centers
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Transthyretin Amyloid Cardiomyopathy Gene Therapy Market

  1. Sustained pivotal outcomes trial progress driving lead-candidate clinical development activity: The MAGNITUDE study’s substantial 1,200-patient enrollment continues to anchor the majority of current ATTR-CM gene-editing development attention.
  2. Growing clinical validation of LNP-delivered systemic gene editing supporting technology-driven developer investment: This delivery platform continues to attract structured research investment given its established application in nex-z’s clinical development.
  3. Continued recognition of wild-type ATTR-CM as a substantial addressable population supporting broader market development: This age-associated population continues to broaden the category’s addressable market beyond genetically defined hereditary disease alone.
  4. Sustained research investment in next-generation CRISPR-Cas3 technology supporting pipeline diversification: Preclinical validation of this editing platform continues to generate incremental developer interest in complementary next-generation approaches.
  5. Growing treatment center preference for single-administration therapy supporting differentiated treatment paradigm adoption: The one-time treatment approach continues to differentiate gene editing from chronic RNA-silencing and stabilizer therapy requiring ongoing administration.
  6. Maturing Phase III program supporting an approaching regulatory decision: Continued MAGNITUDE study progress continues to focus cardiology and amyloidosis treatment center attention on the category’s imminent regulatory milestone.

Regional Outlook: Transthyretin Amyloid Cardiomyopathy Gene Therapy Market

  • North America: The United States accounts for the largest share of regional clinical trial activity, supported by extensive specialized amyloidosis and heart failure center infrastructure and substantial participation in the MAGNITUDE trial; regional treatment centers continue to prepare for potential near-term commercial launch.
  • Europe: Germany, the United Kingdom, and France anchor regional clinical trial activity, supported by growing specialized cardiomyopathy clinic capacity and substantial multinational trial participation; this demand base is expected to remain broadly stable through the forecast period.
  • Asia-Pacific: Japan, China, and South Korea represent some of the fastest-growing regional markets given elevated regional ATTR-CM awareness and expanding specialized amyloidosis center capacity; regional treatment centers continue to invest in the specialized infrastructure required to support this expansion.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as specialized cardiology centers begin to participate in ATTR-CM gene therapy clinical trials; this segment is expected to follow a steady, if more gradual, growth trajectory through 2035.

Competitive Landscape: Transthyretin Amyloid Cardiomyopathy Gene Therapy Market

Key Players
Intellia Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Pfizer Inc., BridgeBio Pharma, Inc., Ionis Pharmaceuticals, Inc.

  • Intellia Therapeutics, Inc. [March 2026] — confirmed continued enrollment progress for its pivotal MAGNITUDE Phase 3 study evaluating nex-z, with the company noting sustained investigator interest in its single-infusion in-vivo gene editing approach.
  • Regeneron Pharmaceuticals, Inc. [December 2025] — reported continued collaborative clinical development of nex-z alongside Intellia Therapeutics, with the company noting sustained commitment to the MAGNITUDE outcomes program.
  • Intellia Therapeutics, Inc. [September 2025] — confirmed the MAGNITUDE study’s continued enrollment toward its target of approximately 1,200 adults with ATTR-CM, with the company noting sustained clinical site engagement across multiple regions.

Consultant POV

The Transthyretin Amyloid Cardiomyopathy Gene Therapy Market’s exceptional 34.0% CAGR outlook through 2035 is anchored in sustained nex-z pivotal outcomes demand, growing LNP-delivered CRISPR/Cas9 editing activity, and continued ATTRwt-CM broad patient population adoption. Sustained clinical investment from companies including Intellia Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., and Alnylam Pharmaceuticals, Inc. confirms the Transthyretin Amyloid Cardiomyopathy Gene Therapy Market will sustain exceptional growth through 2035 as its lead candidate progresses through pivotal development.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report